Meta-analysis shows Tradjenta (Boehringer/Eli Lilly) offers no extra risk of CV events in Type 2 Diabetes patients
Results from a new pooled meta-analysis of Phase III data for Tradjenta (linagliptin), from Boehringer/Eli Lilly, in patients with Type 2 Diabetes, shows a low risk of cardiovascular( CV) events relative to comparative therapies. The CAROLINA post-hoc study compared the incidence of CV events with linagliptin for the treatment of adults with T2D with the incidence of CV events for a number of comparators (placebo, glimepiride and voglibose).
Pooled data from 9,459 patients showed a lower incidence rate of the composite CV endpoint for the linagliptin group (13.4 per 1,000 patient years), versus the comparator group (18.9 per 1,000 patient years), and a hazard ratio of 0.78. Data were presented at the American Diabetes Association 73rd Scientific Sessions.
Learning Zones
The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.
3 mins